Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramiro Garzon

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous LeukemiaTsung-Huei Lai, Brett Ewald, Alma Zecevic, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2018
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector FunctionNina C Zitzer, Katiri Snyder, Xiamoei Meng, et al.
Blood|April 8, 2026
A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemiaMaria L Toribio, María J García-León, Marina García-Peydró, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse modelSukhinder K Sandhu, Stefano Volinia, Stefan Costinean, et al.
Leukemia & Lymphoma|August 20, 2013
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca B Klisovic, Ramiro Garzon, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Blood|June 9, 2012
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Caroline Na, et al.
The Journal of Biological Chemistry|June 23, 2019
Correction: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiationZhaoyong Li, Mohammad Q Hassan, Mohammed Jafferji, et al.
Experimental Hematology|May 20, 2023
Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphomaChinmayee Goda, Sofia Kolovich, Alexander Rudich, et al.
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous LeukemiaTsung-Huei Lai, Brett Ewald, Alma Zecevic, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2018
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector FunctionNina C Zitzer, Katiri Snyder, Xiamoei Meng, et al.
Blood|April 8, 2026
A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemiaMaria L Toribio, María J García-León, Marina García-Peydró, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse modelSukhinder K Sandhu, Stefano Volinia, Stefan Costinean, et al.
Leukemia & Lymphoma|August 20, 2013
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca B Klisovic, Ramiro Garzon, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Blood|June 9, 2012
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Caroline Na, et al.
The Journal of Biological Chemistry|June 23, 2019
Correction: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiationZhaoyong Li, Mohammad Q Hassan, Mohammed Jafferji, et al.
Experimental Hematology|May 20, 2023
Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphomaChinmayee Goda, Sofia Kolovich, Alexander Rudich, et al.
Pageof 14